Stay in touch
We'd love to keep in touch about news, events and how you can get involved. To hear from us, please sign up below.
The Scottish Medicines Consortium (SMC) has today (9 November 2020) approved:
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
“The SMC’s approval of two new treatment options in Scotland holds the promise of changing the lives of hundreds of women with primary and secondary breast cancer for the better.
“For patients with primary breast cancer, access to adjuvant Kadcyla offers an invaluable new line of defence for patients who haven’t fully responded to treatment given to shrink the tumour before surgery, helping to further reduce the risk of the disease coming back, and bringing hope for many people who, until now, have faced a bleaker prognosis.
“Alongside this, approval of atezolizumab with chemotherapy marks a huge leap forward in treatment options for some women with triple negative secondary breast cancer. For these patients, who currently face a heartbreakingly short life expectancy and limited treatment options, access to this treatment could give them the precious chance to live well for longer, having more time with loved ones.
“Both treatments are significant advances driving us towards achieving our ambition that, by 2050, everyone who develops breast cancer will live, and live well.
“Healthcare teams must discuss the associated risks and benefits of these treatments with eligible patients, and this is especially important during the COVID-19 pandemic. Individuals must be given the information and support they need to make treatment decisions that best meet their individual needs. Anyone with questions about breast cancer treatment, including how COVID-19 is impacting on this, can also speak to our expert nurses by calling our free Helpline on 0808 800 6000.”
Notes to editors